We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for streaming realtime charts, analysis tools, and prices.
| Name | Symbol | Market | Type |
|---|---|---|---|
| GSK plc | NYSE:GSK | NYSE | Depository Receipt |
| Price Change | % Change | Price | High Price | Low Price | Open Price | Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|
| 0.23 | 0.53% | 43.58 | 43.68 | 43.27 | 43.58 | 4,048,068 | 01:00:00 |
From May 2019 to May 2024
LONDON--Pharmaceutical company GlaxoSmithKline PLC (GSK.LN) said Tuesday that the U.S. Food and Drug Administration has approved its Tanzeum, or albiglutide, drug for type 2 diabetes treatment.
MAIN FACTS:
-FDA has approved Tanzeum for injection, for subcutaneous use, as a once-weekly treatment for type 2 diabetes.
-Tanzeum has been approved as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.
-Approval is based on the results of the company's Phase III Harmony program.
-Anticipates the U.S. launch of Tanzeum in the third quarter of 2014.
-Albiglutide was licensed by the European Medicines Agency in March 2014, under the brand name Eperzan, for use in adult patients with type 2 diabetes.
-Shares on Tuesday closed at 1547 pence, valuing the company at GBP75.17 billion.
-Write to Tapan Panchal at tapan.panchal@wsj.com
Subscribe to WSJ: http://online.wsj.com?mod=djnwires
1 Year GSK Chart |
1 Month GSK Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
